Disclosures for "Cost-effectiveness of Lecanemab for the Treatment of Early Alzheimer's Disease: A Canadian Societal Perspective"
-
The institution of Mr. Burn has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Eisai Inc.
-
The institution of Mr. Trueman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Eisai Inc.
-
The institution of Ms. Molloy has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Eisai Inc.
-
Mr. Haynes has received personal compensation for serving as an employee of Eisai Canada.
-
Mrs. Castellano has nothing to disclose.
-
Mrs. Pastor has received personal compensation for serving as an employee of EVERSANA.
-
Dr. Wong has received personal compensation for serving as an employee of EVERSANA.
-
Dr. Rothwell has received personal compensation for serving as an employee of Eisai.
-
Miss Jang has received personal compensation for serving as an employee of Eisai Inc.
-
Ms. bodnar has received personal compensation for serving as an employee of Eisai Europe Ltd.